Damian A. Braga has been promoted to the position of president US and vice president, Americas for Sanofi Pasteur, the vaccines division of the sanofi-aventis Group. In his new position, Braga will oversee the company’s Canadian and Latin American businesses, in addition to retaining his current responsibilities as president of the US business.
Braga’s new role provides a more synergistic approach to managing activities in all three regions, particularly as it relates to immunization policies, product positioning, and medical thought leadership.
Braga has spent 19 years with the company, holding several key positions and contributing significantly to its accomplishments. In his last six years as president of the US Business Unit, he has aided the company in increasing US revenues by 20 percent a year, increasing sales to more than $2.0 billion in 2007.
Braga is active on a number of national and local boards. He represents the Pharmaceutical Research and Manufacturers of America (PhRMA) on the Advisory Committee on Immunization Practices to the U.S. Centers for Disease Control and Prevention (CDC). Braga is a board member of the Team Pennsylvania Foundation, and a former vice-chairman of the Pennsylvania Business Roundtable.
Braga earned a bachelor’s degree in Economics from the University of Miami in Coral Gables, Fla., and a master of Business Administration from Seton Hall in South Orange, N.J. He resides in Long Valley, New Jersey with his family.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a 1.6 billion doses of vaccine in 2007, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: http://www.sanofipasteur.com/ or http://www.sanofipasteur.us
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.
